TickerFactsScreenerDevelopers

ImmunityBio, Inc. (IBRX) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2016: -$38.59M2017: -$48.78M2018: -$63.38M2019: -$152.11M2020: -$171.72M2021: -$274.42M2022: -$337.51M2023: -$366.76M2024: -$391.24M2025: -$304.94M-$304.94M
2016Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$304.94M+22.1%
2024-$391.24M-6.7%
2023-$366.76M-8.7%
2022-$337.51M-23.0%
2021-$274.42M-59.8%
2020-$171.72M-12.9%
2019-$152.11M-140.0%
2018-$63.38M-29.9%
2017-$48.78M-26.4%
2016-$38.59M—